Gap19 TFA is widely used in biomedical research for its ability to selectively inhibit connexin 43 (Cx47) hemichannels without affecting gap junction communication. This property makes it a valuable tool in studying cellular processes involving Cx43, particularly in conditions where uncontrolled hemichannel opening contributes to pathology. It is applied in research models of inflammation, ischemia, and neurodegenerative diseases, such as stroke and Alzheimer's disease, where it helps reduce cell death and inflammatory responses. Due to its specificity and cell-permeable nature, Gap19 TFA is also used in cardiac studies to mitigate damage following myocardial infarction and in skin research to modulate wound healing and inflammation. Its role in dissecting hemichannel-specific effects supports the development of targeted therapies with fewer side effects.